Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Key Points

• Second-line therapy with DKN-01 and tislelizumab shows potential effectiveness.
• Efficacy observed in patients with high levels of DKK1, indicating a specific biomarker.
• Observational data from the DisTinGuish trial suggests favorable treatment outcomes.
• Implications for targeted therapies in gastroesophageal adenocarcinoma treatment strategy.